← Bioventus Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | $6.3m |
$14.7m
+133.76%
|
$9.6m
-34.89%
|
($213.4m)
-2326.07%
|
($195.6m)
+8.33%
|
($43.8m)
+77.59%
|
$27.3m
+162.22%
|
— | |
| Depreciation and amortization | $30.3m | $28.6m | $34.9m | $66.8m | $57.4m | $49.6m | $47.0m | $45.2m | |
| Deferred income taxes | ($348k) | ($511k) | ($9.8m) | ($52.8m) | ($2.4m) | ($5.4m) | ($909k) | ($23.1m) | |
| Impairments of assets | — | $0 | $0 | $199.5m | $78.6m | $36.4m | $0 | — | |
| Accounts receivable | ($14.9m) | ($3.9m) | ($20.1m) | ($18.0m) | $10.1m | ($10.7m) | ($916k) | ($6.9m) | |
| Inventory | ($1.4m) | ($528k) | $3.2m | ($18.6m) | ($6.0m) | ($16.4m) | $8.6m | $13.6m | |
| Accounts payable and accrued expenses | $6.6m | $20.5m | $18.2m | $10.9m | ($5.3m) | $17.8m | ($19.8m) | — | |
| Accounts payable for purchase of property, plant and equipment | $34k | $336k | $695k | $419k | $1.3m | $42k | $240k | — | |
| Accrued liabilities for distribution rights and member distributions | — | — | $3.2m | $0 | $709k | $0 | $0 | — | |
| Other current and noncurrent assets and liabilities | ($3.9m) | ($733k) | ($14.6m) | $11.2m | ($2.0m) | ($2.5m) | ($1.7m) | — | |
| Net cash from operating activities - continuing operations | $42.5m |
$72.2m
+69.70%
|
$23.0m
-68.16%
|
($13.5m)
-158.88%
|
$17.5m
+229.37%
|
$38.8m
+121.52%
|
$74.7m
+92.48%
|
$96.9m
+29.73%
|
|
| Net cash from operating activities - discontinued operations | ($1.8m) |
($400k)
+78.17%
|
$0
+100.00%
|
$0 | ($2.2m) |
$0
+100.00%
|
$0 | $96.9m | |
| Net cash from operating activities | $40.7m |
$71.8m
+76.35%
|
$23.0m
-67.98%
|
($13.5m)
-158.88%
|
$15.3m
+213.35%
|
$38.8m
+152.83%
|
$74.7m
+92.48%
|
$96.9m
+29.73%
|
|
| Purchase of property and equipment | ($2.3m) | ($4.1m) | ($7.4m) | ($10.0m) | ($7.4m) | ($1.0m) | ($2.6m) | ($2.6m) | |
| Investments and acquisition of distribution rights | ($6.0m) | ($16.6m) | ($13.5m) | ($1.5m) | $0 | ($709k) | $0 | — | |
| Net cash from investing activities - continuing operations | ($7.9m) | ($20.7m) | ($283.8m) | ($116.4m) | $27.3m | $23.0m | ($3.2m) | — | |
| Net cash from investing activities - discontinued operations | $0 | $172k | $0 | $0 | ($11.5m) | $0 | $0 | — | |
| Net cash from investing activities | ($7.9m) | ($20.5m) | ($283.8m) | ($116.4m) | $15.8m | $23.0m | ($3.2m) | — | |
| Borrowing on revolver | $0 | $49.0m | $20.0m | $25.0m | $64.0m | $0 | $45.0m | — | |
| Proceeds from the issuance of long-term debt, net of discount | $198.1m | $0 | $257.5m | $79.7m | $0 | $0 | $31.9m | — | |
| Payments on the extinguishment of long-term debt | — | — | — | — | $0 | $0 | ($65.8m) | — | |
| Debt financing costs | — | — | $0 | $0 | ($3.7m) | ($1.2m) | ($697k) | — | |
| Payments on long-term debt | ($199.5m) | ($10.0m) | ($91.2m) | ($20.0m) | ($38.3m) | ($44.6m) | ($9.1m) | — | |
| Proceeds from issuance of Class A and B common stock | $0 | $0 | $1.6m | $5.8m | $778k | $2.4m | $2.1m | — | |
| Net cash from financing activities | ($11.0m) |
($29.6m)
-170.01%
|
$273.4m
+1024.52%
|
$62.1m
-77.29%
|
($26.7m)
-142.94%
|
($54.6m)
-104.78%
|
($62.1m)
-13.85%
|
— | |
| Cash and cash equivalents at the beginning of the period | $64.5m | $86.8m | $99.2m | $31.8m | $37.0m | $41.6m | $51.2m | — | |
| Effect of exchange rate changes on cash | ($104k) | $589k | ($228k) | $521k | $629k | ($2.6m) | $371k | ($1.2m) | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Less: Loss from discontinued operations, net of tax | $1.8m | $0 | $0 | ($68.7m) | ($74.4m) | $0 | $0 | — | |
| Income (loss) from continuing operations | $8.1m | $14.7m | $9.6m | ($144.7m) | ($121.2m) | ($43.8m) | $27.3m | — | |
| Provision (benefit) for expected credit losses | $2.2m | $1.2m | $485k | $5.2m | ($1.1m) | ($434k) | $1.3m | — | |
| Equity-based compensation | $0 | $0 | $19.8m | $17.6m | $2.7m | $10.1m | $12.7m | — | |
| Change in fair value of contingent consideration | $0 | $0 | $829k | $6.5m | $719k | $1.4m | $0 | — | |
| Loss on extinguishment | $3.4m | $0 | $2.2m | $0 | $0 | $0 | $326k | — | |
| Loss on disposals | — | — | $0 | $0 | $3.6m | $292k | $81k | — | |
| Unrealized (gain) loss on foreign currency fluctuations | — | ($490k) | $472k | $1.4m | $665k | ($259k) | ($360k) | — | |
| Other, net | ($448k) | $317k | ($37k) | ($15k) | ($506k) | ($758k) | ($827k) | — | |
| (Settlement) proceeds from the sale of a business | — | — | — | — | $34.7m | $24.7m | ($686k) | — | |
| Tax withholdings on equity-based compensation | — | $0 | $0 | ($3.4m) | $0 | $0 | ($9k) | — | |
| Receipt of deferred consideration | — | — | — | $0 | $0 | $4.5m | $0 | — | |
| Payment of contingent consideration | — | — | — | — | $0 | $0 | ($19.8m) | — | |
| Payment on revolver | $0 | ($49.0m) | ($20.0m) | ($25.0m) | ($49.0m) | ($15.0m) | ($45.0m) | — | |
| Net change in cash and cash equivalents | $21.7m | $22.3m | $12.4m | ($67.4m) | $5.1m | $4.6m | $9.7m | — |